Clinical trial
Single-Arm Bayesian Phase II Trial of Self-Applied Transcutaneous Auricular Vagus Nerve Stimulation for Chemotherapy-Induced Peripheral Neuropathy
NCT07925580 is registered in ClinicalTrials.gov with University of Miami as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- Single-Arm Bayesian Phase II Trial of Self-Applied Transcutaneous Auricular Vagus Nerve Stimulation for Chemotherapy-Induced Peripheral Neuropathy
- Lead sponsor
- University of Miami
- Phase
- Not applicable
- Overall status
- Not yet recruiting
- Start date
- January 31, 2027
- Completion date
- December 30, 2029
- Enrollment
- 55 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
chemotherapy induced peripheral neuropathy (cipn)
Arms
As registered; 1 arm.
-
Auricular Vagus Nerve (AVNS) Group
Participants in this group will receive a 2-week course of daily self-applied transcutaneous auricular vagus nerve stimulation (taVNS). Participants will use a portable taVNS device at home once daily for 14 consecutive days, applying stimulation to the auricular vagus nerve according to standardized instructions provided by the study team. Each stimulation session will last approximately 60 minutes.
Primary endpoints
Registered primary outcome measures; 1 primary.
-
Change in Daily Chemotherapy-Induced Peripheral Neuropathy Symptom Severity Measured by Numeric Rating Scale (NRS)
Participants will complete a daily electronic diary rating the severity of their most bothersome chemotherapy-induced peripheral neuropathy (CIPN) symptom (pain, numbness/tingling, burning, pressing/squeezing, or electric shocks) during the previous 24 hours using an 11-point Numeric Rating Scale (NRS), where 0 = no symptoms and 10 = worst imaginable symptoms. The primary analysis evaluates symptom trajectories using daily observations collected during the baseline and treatment periods.
Lead sponsor's other trials
University of Miami, most recent start first.
+836 more trials See the organization page
Similar trials
Same condition (Neuralgia) and phase, most recent start first.
+377 more trials See the condition page